≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research.
In Vitro
Obeldesivir (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern. Obeldesivir has an overall >4-fold and >12-fold potency improvement in inhibiting the replication of Delta and Omicron variants, with EC 50 values of 0.349 μM and 0.106 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Obeldesivir (5-25 mg/kg; p.o. and i.v.; Sprague Dawley rats) has favorable pharmacokinetic profiles in rats with high oral bioavailability (F %) of 81.5% and maximum blood concentration (C max ) of 8.2 μM . Obeldesivir (250-500 mg/kg; p.o.; daily, for 4 days; hACE2 knock-in and Ad5-hACE2 mice) has antiviral activity and inhibits SARS-CoV-2 replication in mouse models . Obeldesivir (100-250 mg/kg; p.o.; daily, for 10 days) reduces lung damage and protects K18-hACE2 mice . Obeldesivir (10-150 mg/kg; p.o.; daily, for 3 days) reduces virus titers and lung damage caused by Delta variant infection in K18-hACE2 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague Dawley rats Dosage: 5 and 25 mg/kg Administration: Oral administration (25 mg/kg) and intravenous injection (5 mg/kg) Result: 1.19 parameters i.v. (5 mg/kg) p.o. (25 mg/kg) AUC last (μM·h) 5.6 22.8 T 1/2 (h) 1.5 1.2 T max (h) 0.5 C max (μM) 8.7 8.2 F % 81.5 Animal Model: hACE2 knock-in and Ad5-hACE2 mice Dosage: 250 and 500 mg/kg Administration: Oral administration; daily, for 4 days Result: Inhibited gRNA and sgRNA, which is Biomarkers of coronavirus replication. Reduced the viral load and pathological damage of the lung. Animal Model: K18-hACE2 mice Dosage: 100 and 250 mg/kg Administration: Oral administration; daily, for 10 days Result: Reduced viral RNA and increased the survival rate of mice. Reduced evidence of lung pathology and the production of inflammatory cytokines and chemokines in the lung tissues. Animal Model: K18-hACE2 mice Dosage: 10, 30, 80 and 150 mg/kg Administration: Oral administration; daily, for 3 days Result: Reduced viral load in a dose-dependent manner and alleviated the symptoms in the lung.
Form:Solid
| Isomères SMILES | CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O |
|---|---|
| PubChem CID | 162513664 |
| Poids moléculaire | 361.35 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubilité | DMSO : 250 mg/mL (691.85 mM; Need ultrasonic) |
|---|
